<DOC>
	<DOCNO>NCT00788593</DOCNO>
	<brief_summary>The primary efficacy objective study evaluate difference coefficient fat absorption ( CFA ) participant treat high dose EUR-1008 ( APT-1008 ) versus low dose EUR-1008 ( APT-1008 ) treatment sign symptom malabsorption participant EPI associate CP . This study sponsor Aptalis Pharma ( formerly Eurand ) .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Dose Response-Control , Crossover Study Evaluate Safety Efficacy Two Doses EUR-1008 ( APT-1008 ) Chronic Pancreatitis ( CP ) Participants With Exocrine Pancreatic Insufficiency ( EPI )</brief_title>
	<detailed_description>After screen , eligible participant start placebo baseline ambulatory phase ( 4 day ) . On day 5 , hospitalize three five day , undergo `` baseline '' 72-hour CFA determination control diet use stool marker indicate begin end control diet period , continue receive placebo treatment . At end placebo baseline phase , participant randomize `` high dose follow low dose '' `` low dose follow high dose '' EUR-1008 ( APT-1008 ) dose sequence proceed first crossover ( treatment ) phase . Each crossover ( treatment ) phase consist stabilization period six day home , follow hospitalization three five day undergo 72-hour CFA determination use control diet use stool marker indicate begin end control diet period . Participants immediately proceed first crossover ( treatment ) phase second without washout period return-to-baseline period phase . Participants stabilize home 6 day . Any residual lipase prior treatment phase likely negligible influence subsequent CFA determination participant take new dose level ( high low ) six day begin sample collection new CFA . This interval enough time CFA reflective new dose .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Participants male female Participants age 18 year Participants write , legally valid informed consent Women childbearing potential must use medically acceptable form birth control 30 day prior begin study agree maintain adequate birth control measure whole duration study plus additional 30 day well negative pregnancy test screen Visit 3 Visit 7 Participants document diagnosis CP medical history prefer support image evidence confirm CP include : abnormal endoscopic retrograde cholangiopancreatography ( ERCP ) ( Cambridge Class 4 ) , abnormal compute tomography ( CT ) scan ( dilate main pancreatic duct , atrophy pancreas calcification ) , abnormal ultrasound , endoscopic ultrasound least 5 abnormality note In case pancreatic surgery , participant include partial distal resection pancreas ( due cancer ) Participants document EPI target fecal elastase ( FE ) less equal 100 microgram per gram ( mcg/g ) stool use monoclonal test ( pancreatic elastase 1 [ PE1 ] Genova Diagnostics ) perform screen visit . The mean coefficient variation ( CV ) FE test 20 percent ( % ) Participants know investigator significant medical and/or mental disease would compromise participant 's welfare , pose unacceptable risk him/her confound study result Participants participate clinical trial within 30 day randomization per specific country regulations/guidelines Participants cystic fibrosis Participants excessive alcohol consumption Participants drug abuse Participants contraindicate medication unable discontinue prohibit concomitant medication Participants uncontrolled diabetes mellitus Participants allergic pork protein/unwilling ingest pork product Participants atopic predisposition multiple drug hypersensitivity , allergic asthma , urticaria , relevant allergic diathesis Participants pregnant lactate Participants acute pancreatitis acute exacerbation chronic pancreatitis Participants acute biliary disease Participants malabsorption syndrome cause metabolic disease surgery , relate exocrine pancreatic insufficiency Participants resection stomach gastrointestinal tract affect transit time and/or gastric emptying . Participants evidence active gastric duodenal ulcer Participants chronic inflammatory bowel disease Participants history pancreatic cancer noncutaneous malignancy ( except basal cell squamous cell carcinoma skin situ remove reoccurred 5 year ) Participants viral hepatitis infectious virion blood and/or body fluid ( etiology ) Participants human immunodeficiency virus ( HIV ) infection Participants hyperuricemia ( great [ &gt; ] 1.5 time upper normal value lab ) Participants acute chronic disease , opinion investigator could influence study result pose risk participant ' safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Chronic Pancreatitis</keyword>
	<keyword>Exocrine Pancreatic Insufficiency</keyword>
</DOC>